BioPharmSignal logoBioPharmSignal

Biotech News

Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

Revolution Medicines (RVMD)Revolution MedicinesEarnings

Received U.S. FDA approval and launched RASONQUE ® (daraxonrasib) for adult patients with metastatic pancreatic cancer who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy Reported RASONQUE net product revenue of $198 million for the

Related news

RVMDRevolution Medicines2026-10-21 20:05 EST

Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026

EXELExelixis2026-10-29 20:05 EST

Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update

RLAYRelay Therapeutics2026-10-28 20:12 EST

Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026

BNTXBioNTech2026-10-20 10:45 EST

BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026

NRIXNurix Therapeutics2026-10-12 20:05 EST

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

REPLReplimune Group2026-10-28 11:00 EST

Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update

REPLReplimune Group2026-10-22 12:00 EST

Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026

IMCRImmunocore Holdings plc2026-11-06 14:00 EST

Immunocore reports third quarter financial results and provides a business update

ELVNEnliven Therapeutics2026-11-05 21:05 EST

Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update

COGTCogent Biosciences2026-11-05 21:02 EST

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results

View all latest news

Revolution Medicines

RAS(ON) Inhibitors Revolution Medicines develops oral targeted therapies that bind active, GTP-loaded RAS proteins. Its portfolio covers multiple RAS mutations and combination strategies across pancreatic and lung cancers. Daraxonrasib Daraxonrasib is a multi-selective RAS(ON) inhibitor and the company's lead late-stage asset. It has...

Recent company news

RVMDRevolution Medicines2026-11-04 21:02 EST

Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

RVMDRevolution Medicines2026-10-27 20:05 EST

Revolution Medicines to Participate in November 2026 Investor Conferences

RVMDRevolution Medicines2026-10-23 11:30 EST

Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026

RVMDRevolution Medicines2026-10-21 20:05 EST

Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026

RVMDRevolution Medicines2026-10-20 12:00 EST

Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer

Stock data

Close
177.65 USD
Market cap
32.17B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States